Press Releases
AtriCure to Participate in Upcoming Investor Conferences
October 25, 2022
MASON, Ohio --(BUSINESS WIRE)--Oct. 25, 2022-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in upcoming...
AtriCure to Announce Third Quarter 2022 Financial Results
October 11, 2022
MASON, Ohio --(BUSINESS WIRE)--Oct. 11, 2022-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its third quarter...
AtriCure Announces Investor Education Webcast with Hybrid AF Therapy Key Opinion Leaders
September 06, 2022
MASON, Ohio --(BUSINESS WIRE)--Sep. 6, 2022-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will host an investor education...
AtriCure to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
August 16, 2022
MASON, Ohio --(BUSINESS WIRE)--Aug. 16, 2022-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the...
AtriCure Reports Second Quarter 2022 Financial Results
August 02, 2022
MASON, Ohio --(BUSINESS WIRE)--Aug. 2, 2022-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced second quarter 2022 financial results....
AtriCure to Participate at Upcoming Investor Conferences
July 20, 2022
MASON, Ohio --(BUSINESS WIRE)--Jul. 20, 2022-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in two...
AtriCure to Announce Second Quarter 2022 Financial Results
July 12, 2022
MASON, Ohio --(BUSINESS WIRE)--Jul. 12, 2022-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its second...
AtriCure Announces the First Patient Treated in the HEAL-IST Clinical Trial
June 07, 2022
Trial will evaluate the safety and effectiveness of AtriCure’s Isolator® Synergy ™ Clamp in conjunction with endocardial catheter ablation for the treatment of Inappropriate Sinus Tachycardia MASON, Ohio --(BUSINESS WIRE)--Jun. 7, 2022-- AtriCure, Inc....
AtriCure Announces the Appointment of Deborah Yount as Chief Human Resources Officer
June 01, 2022
MASON, Ohio --(BUSINESS WIRE)--Jun. 1, 2022-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, announced the appointment of Deborah Yount as Chief...
AtriCure Reports First Quarter 2022 Financial Results
May 03, 2022
MASON, Ohio --(BUSINESS WIRE)--May 3, 2022-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced first quarter 2022 financial results....